Novoheart Announces Revolving Credit Facility

VANCOUVER, British Columbia, April 10, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSXV: NVH; FWB: 3NH) announces that its subsidiary, Novoheart Limited (Hong Kong), has entered into a demand revolving credit facility for up to HKD$ 30 million (approximately $5 million) (the "Facility") with The Hongkong and Shanghai Banking Corporation ("HSBC" or the "Lender") effective April 8, 2019. The Facility bears interest at a rate per annum equal to 1, 3 or 6-months Hong Kong Interbank Offered Rate plus 1.20%. The Facility is subject to review at any time and in any event by November 1, 2019.

The Company intends to use the proceeds of the Facility for general working capital purposes, and expects that the Facility will be repaid upon the success of the Company's commercialization efforts and/or receipt of other sources of financing. The Lender requires a monthly report on usage of the proceeds.

About Novoheart:

Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart's bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.

For further information, please contact:
Ronald Li, CEO
[email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the availability of and use of proceeds from the Facility, success of the Company's commercialization efforts, raising additional or alternative financing, the Company's future plans, its goals and expectations, and the potential applications of its MyHeart^TM platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.'s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.